Researchers decode molecular action of combination therapy for a deadly thyroid cancer

23 julio 2015

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers have demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/1fmPy4DCSnk» height=»1″ width=»1″ alt=»»/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/1fmPy4DCSnk/150723101117.htm

Volver